Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
Clinical trial NCT04670913 · UNKNOWN
Trial details
- NCT number
- NCT04670913
- Sponsor
- Junling Li
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-28
- Primary completion
- 2021-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.